2608.5000 -37.60 (-1.42%)
NSE Nov 19, 2026 15:31 PM
Volume: 392.8K
 

Motilal Oswal
Glenmark Pharma (GNP) posted a marginally lower-than-expected operating performance in 4QFY25 (2%/5% miss on revenue/EBITDA). Elevated interest outgo and lower other income led to a 16% miss on earnings.
Glenmark Pharma has gained 41.55% in the last 1 Year
More from Glenmark Pharmaceuticals Ltd.
Recommended